Fast and precise quantification of serum biomarkers and simultaneous recognition of multiple diseases enabled by stable isotope-labelled peptides assistant high-throughput MRM strategy
Serum/plasma holds promise as an important source of disease-related proteins even biomarkers in clinical practice. However, discovery of biomarker candidates in serum/plasma remain challenging. In this study, we constructed a MS strategy that enables fast and precise quantification of serum biomarkers through coupling high-throughput scheduled MRM strategy with stable isotope labelled (SIL) peptides panel from more than 500 plasma proteins as internal standards. With this strategy, we discovered relevant serum proteins of atherosclerosis (AS), lung cancer (LC) and breast cancer (BC) , which can recognize these diseases simultaneously. The above results indicate that the powerful strategy we constructed holds the potential for serum biomarker screening and disease detection.